Compare CMT & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMT | QNCX |
|---|---|---|
| Founded | 1996 | 2012 |
| Country | United States | United States |
| Employees | 1570 | N/A |
| Industry | Electronic Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.4M | 167.0M |
| IPO Year | 1996 | 2019 |
| Metric | CMT | QNCX |
|---|---|---|
| Price | $18.86 | $0.12 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 16.2K | ★ 123.6M |
| Earning Date | 01-01-0001 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.93 | N/A |
| Revenue | ★ $284,290,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.66 | N/A |
| P/E Ratio | $20.89 | ★ N/A |
| Revenue Growth | ★ 5.49 | N/A |
| 52 Week Low | $12.25 | $0.13 |
| 52 Week High | $22.29 | $4.55 |
| Indicator | CMT | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 40.10 | 27.25 |
| Support Level | $17.81 | N/A |
| Resistance Level | $19.58 | $0.98 |
| Average True Range (ATR) | 0.69 | 0.10 |
| MACD | -0.09 | 0.09 |
| Stochastic Oscillator | 0.00 | 2.22 |
Core Molding Technologies Inc operates in the engineered materials market as one operating segment as a molder of thermoplastic and thermoset structural products. It produces and sells molded products for varied markets, including medium and heavy-duty trucks, automobiles, power sports, construction and agriculture, building products, and other industrial markets. The processes include compression molding of sheet molding compound (SMC), resin transfer molding (RTM), liquid molding of dicyclopentadiene (DCPD), spray-up and hand-lay-up, direct long-fiber thermoplastics (D-LFT) and structural foam, and structural web injection molding (SIM). It operates operates in Columbus, Ohio; Gaffney, South Carolina; Winona, Minnesota; Matamoros and Escobedo, Mexico; and Cobourg, Ontario, Canada.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.